NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
Clinical Trials
32 trialsNCT05122091 2024-02-26
Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma
Guangxi Medical University
Phase 2 Unknown
NCT05435313 2024-01-17
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Phase 2 Unknown
NCT05522738 2024-01-08
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05795296 2023-08-30
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
RenJi Hospital
Phase 2 Unknown
NCT05993702 2023-08-15
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
China Medical University, China
Unknown
NCT05982834 2023-08-09
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Fudan University
Phase 1/2 Unknown
NCT05971199 2023-08-02
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05763927 2023-03-10
Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT
West China Hospital
Phase 2 Unknown
NCT05643677 2022-12-09
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Fujian Medical University
Phase 2 Unknown
NCT05636150 2022-12-05
A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05634590 2022-12-02
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT05635149 2022-12-02
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Unknown
NCT05575635 2022-10-12
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
Henan Provincial People's Hospital
Phase 2 Unknown
NCT05511051 2022-08-22
A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT04866108 2022-08-18
A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
Beijing Friendship Hospital
Phase 2 Unknown
NCT05004831 2022-08-18
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
Sun Yat-sen University
Phase 2 Unknown
NCT04924179 2022-08-17
Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
Huazhong University of Science and Technology
Phase 2 Unknown
NCT04733963 2022-07-26
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04866862 2022-07-25
Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05451719 2022-07-12
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT05447715 2022-07-07
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT05406206 2022-06-06
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05292417 2022-03-31
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT05241899 2022-02-16
A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05168527 2022-01-14
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
Fudan University
Phase 2 Unknown
NCT04582981 2021-10-26
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT04948034 2021-08-27
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
Fudan University
Phase 2 Unknown
NCT04989855 2021-08-04
Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score
Sun Yat-sen University
Phase 2 Unknown
NCT04431791 2020-06-16
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
Peking University
Unknown
NCT04179084 2019-11-26
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT04156958 2019-11-08
FSTAMBTA
Sichuan University
Phase 2 Unknown